Relevant bibliographies by topics / Triptoreline

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Triptoreline'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Triptoreline.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Triptoreline"

1

Rossi, E., G. Esposito, F. Di Rella, A. Gravina, G. Landi, F. Nuzzo, C. Pacilio, K. Monaco, M. Piccirillo, and A. de Matteis. "Endocrine effects of letrozole + triptoreline compared to tamoxifen + triptoreline as adjuvant treatment of premenopausal patients with early breast cancer." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 578. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.578.

Full text
Abstract:
578 Background: Few data have been reported on endocrine effects of combining LHRH-analogues with aromatase inhibitors (AI) in premenopausal patients. However, promising data in postmenopausal patients make this information interesting in view of extending adjuvant AI to premenopausal patients. We are conducting a phase 3 trial (Hormonal adjuvant treatment bone effects (HOBOE)) comparing tamoxifen (Tam), letrozole (L) and L + zoledronate (Z) for the effect on bone mineral density at 1 year. Postmenopausal and premenopausal patients are eligible, the latter also receiving monthly triptorelin (Tr). Methods: This analysis is limited to 76 premenopausal patients with early endocrine-responsive breast cancer, 28 treated with Tam+Tr and 48 with L+Tr±Z, assuming that Z has no endocrine effects. Serum 17-β-estradiol, FSH, LH, Δ4-androstenedione, testosterone, dehydroepiandrosterone-solphate, progesterone, ACTH and cortisol are measured at baseline and after 6 months of treatment. We compared, for each hormone, 6-month values between treatment groups by applying Exact Wilcoxon-Mann-Whitney test. Results: Baseline values for all the hormones were comparable between treatment groups. At 6 months, statistically significant differences were found for estradiol, FSH, LH and cortisol (see table , with median and range values by treatment group). No differences were found in plasma levels of testosterone, progesterone, ACTH, androstenedione, and dehydroepiandrosterone between the two groups. Conclusions: These data support that letrozole compared to tamoxifen, in combination with triptorelin, induces a more intense estrogen suppression also in premenopausal patients. Such evidence makes reasonable the hypothesis that the higher efficacy of letrozole versus tamoxifen shown in postmenopausal patients could be confirmed also in premenopausal patients. [Table: see text] No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
2

Rossi, E., F. Perrone, G. Esposito, G. Landi, F. Di Rella, R. Thomas, C. Gallo, K. Monaco, A. Morabito, and A. de Matteis. "2050 POSTER Endocrine effects of adjuvant letrozole plus triptoreline versus tamoxifen plus triptoreline in premenopausal patients with early breast cancer." European Journal of Cancer Supplements 5, no. 4 (September 2007): 199. http://dx.doi.org/10.1016/s1359-6349(07)70812-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Siyanti, Nur. "Tinjauan Maqâshid al-Syarî’ah terhadap Hukuman Kebiri bagi Pelaku Tindak Pidana Pedophilia." Al-Jinayah: Jurnal Hukum Pidana Islam 3, no. 1 (March 22, 2018): 113–43. http://dx.doi.org/10.15642/aj.2017.3.1.113-143.

Full text
Abstract:
Abstract: Castration against felons involving in pedhofilia is proposed Indonesia. The proposal considered it as additional punishment. Castration can be done by getting rid of testicle or by injecting antiandrogen hormone such as cyproterone acetate (CPA), medroxyprogesterone acetate (MPA), leuprolide dan triptoreline which function to weaken testosterone hormone. Pedofilia is a sexually based crime targeting children by felons who suffer from abnormal sexual development. From the perspective of maqâshid al-syarî’ah, castration can be considered a part of protection of reason (hifzh al-‘aql). It should prevent perpetrator from doing such an evil deed and will protect community from this wrong doing. Keywords: Pedofilia, castration, maqâshid al-syarî’ah Abstrak: Hukuman kebiri bagi pelaku tindak pidana pedofilia merupakan tambahan hukuman berupa tindakan bedah dengan cara membuang testis sebagai penghasil hormon testosteron, atau dengan suntik kimia, yaitu dengan menyuntikkan hormon anti androgen seperti cyproterone acetate (CPA), medroxyprogesterone acetate (MPA), leuprolide dan triptoreline yang berfungsi untuk melemahkan hormon testosteron, yang diberikan kepada pelaku atas kejahatan yang dilakukan terhadap anak akibat kelainan perkembangan seksual pelaku yang abnormal. Maqâshid al-syarî’ah memandang bahwa tambahan hukuman kebiri, baik yang melalui metode bedah ataupun suntik kimia, bagi pelaku tindak pidana pedofilia adalah sebagai upaya dalam melindungi terpeliharanya akal (hifzh al-‘aql) dan relevan dengan tujuan hukum Islam, yaitu untuk melindungi masyarakat dari rasa takut akan ancaman kejahatan tersebut. Hukuman tersebut diharapkan mampu memberikan efek jera bagi pelaku, serta berfungsi preventif terhadap kemungkinan terjadinya pengulangan jenis kejahatan yang sama, dan represif dalam mendidik pelaku agar ia menjadi orang yang baik dan menyadari kesalahan. Kata Kunci: Maqâshid al-syarî’ah, hukuman kebiri, pedofilia.
APA, Harvard, Vancouver, ISO, and other styles
4

Quereda, F., J. Barroso, and P. Acién. "Individual and combined effects of triptoreline and gestrinone on experimental endometriosis in rats." European Journal of Obstetrics & Gynecology and Reproductive Biology 67, no. 1 (July 1996): 35–40. http://dx.doi.org/10.1016/0301-2115(96)02435-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Paule, B., N. Brion, and M. Truffinet. "Treatment of stage D2 prostate carcinoma with triptoreline (LH-RH agonist)/flutamide/cyclophosphamide. A pilot study." European Journal of Pharmacology 183, no. 5 (July 1990): 1701–2. http://dx.doi.org/10.1016/0014-2999(90)92000-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Saldana, Carolina, Laurent Salomon, Benoit Rousseau, Marie Chaubet-Houdu, Charlotte Joly, Guillaume Ploussard, Yves Allory, Christophe Tournigand, and Alexandre de la Taille. "Weekly paclitaxel versus ADT alone in localized high-risk prostate cancer: Results of a single-institution phase II trial." Journal of Clinical Oncology 33, no. 7_suppl (March 1, 2015): 37. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.37.

Full text
Abstract:
37 Background: Adjuvant chemotherapy’s role after radical prostatectomy (RP) remains controversial in localized high-risk prostate cancer (HRPC). This phase II trial assessed the combination of weekly paclitaxel (WP) with androgen deprivation therapy (ADT) in this population. Methods: All eligible patients (pts) had undergone a laparoscopic RP with pelvic lymph node dissection for a localized HRPC defined with ≥1 of the following criteria: T3b-T4 post-operated Gleason score (GS) ≥8, PSA≥ 20 ng/mL, pN+, in Henri Mondor Hospital. Pts were randomly assigned to either triptoreline 11.25mg every 3 months during 3 years and 8 cycles of WP 100 mg/ m2 (WP arm, n=21) or triptoreline alone (ADT arm, n=26). The primary endpoint is disease free survival (DFS); events=PSA relapse, clinical and radiographic relapse, death. The planned number of pts was 152. Toxicity results indicated a good tolerability with neutropenic fever in 4.3% (n=1), and no negative impact on QoL in the WP arm (Ploussard, Prostate Cancer Prostatic Dis. 2010). Here we report 8-year DFS and overall survival (OS) results. Results: Between February 2005 and October 2007, 47 pts were enrolled. This trial was terminated prematurely because of slow accrual. After a mean follow-up of 8.4 y, we identified a PSA relapse in 25 pts (53%) and castrate-resistant prostate cancer occurred in 6 pts. No statistically difference was found in terms of either biochemical or clinical DFS (bDFS, cDFS) and OS: 8-year bDFS rate: 50% [n=11/22] in the WP arm vs 46% [n=12/26] in the ADT arm (p=0.79); 8-year cDFS rate: 95.4% [n=21/22] in the WP arm vs 88.5% [n=23/26] in the ADT arm (p=0.38). The 8-year OS rate is 90.9% (n=20/22) and 84.6% (n=22/26) respectively with no difference between treatment arms (p=0.51). No clinical, histological or biological variable demonstrated a difference in either 8-year bDFS, cDFS or OS rate. Conclusions: Provided that this trial is probably underpowered to detect a DFS benefit, adjuvant weekly paclitaxel after RP was not associated with any significant reduction in the risk of biological relapse or death compared to ADT alone in patients with localized HRPC. Chemotherapy should be only proposed in dedicated clinical trial for localized HRPC.
APA, Harvard, Vancouver, ISO, and other styles
7

Porcu, Eleonora, Luca Dal Prato, Renato Seracchioli, Raffaella Fabbri, Maria Longhi, and Carlo Flamigni. "Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results." Fertility and Sterility 62, no. 1 (July 1994): 126–32. http://dx.doi.org/10.1016/s0015-0282(16)56827-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Roussie, M., D. Royère, M. Guillonueau, J. Lansac, and J. P. Muh. "Human antral fluid IGF-I and oocyte maturity: effect of stimulation therapy." Acta Endocrinologica 121, no. 1 (July 1989): 90–94. http://dx.doi.org/10.1530/acta.0.1210090.

Full text
Abstract:
Abstract. Studies in animals have highlighted a possible role for growth factors, particularly IGF-I on cellular replication and cytodifferentiation in the ovary. At this time, few studies have been performed about IGF-I in the human ovary. From 38 women undergoing in Vitro Fertilization 293 antral fluids were collected and assessed for steroids (estradiol and progesterone), FSH and IGF-I. Two induction treatments were compared: clomiphene citrate/hMG (group A, N = 15), triptoreline/hMG (group B, N = 23). We also studied relationships between quantitative parameters and oocyte collection or oocyte corona cumulus complex maturity. In group B, the highest antral estradiol levels were found in follicles yielding an oocyte (p <0.05). Concerning antral progesterone, higher levels were observed in follicles collected from group A than in follicles collected from group B (p < 0.05); for this parameter, the highest levels were observed when an oocyte was harvested, whatever the treatment (p <0.05). Highest antral FSH levels were observed in group B (p <0.05). IGF-I levels were higher in follicles collected from group B than in follicles collected from group A (p <0.05) and antral IGF-I levels differed between mature and immature oocyte corona cumulus complex in group B (p <0.05). These results, which are in keeping with studies about biological action of IGF-I in animal or human follicles or granulosa cells, led us to hypothesize a role for IGF-I in human follicular recruitment and maturation, a role that possibly is enhanced during GnRH analogue and gonadotropin therapy.
APA, Harvard, Vancouver, ISO, and other styles
9

Grimaldi, C., H. Bleiberg, F. Gay, M. Messner, P. Rougier, T. C. Kok, L. Cirera, et al. "Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial." Journal of Clinical Oncology 16, no. 2 (February 1998): 411–17. http://dx.doi.org/10.1200/jco.1998.16.2.411.

Full text
Abstract:
PURPOSE The aim of the study was to evaluate the efficacy of antiandrogen therapy on overall survival and response in unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS A total of 244 patients with unresectable HCC were included in this multicentric double-blind trial. According to a two-by-two factorial design, patients were randomly assigned to receive one of the following treatments: pure antiandrogen plus placebo (A+P group, 60 patients); luteinizing hormone-releasing hormone (LHRH) agonist plus placebo (LHRH+P group, 62 patients); pure antiandrogen plus LHRH agonist (A+LHRH group, 62 patients); or placebo plus placebo (P+P group, 60 patients). Pure antiandrogen consisted of Anandron (Roussel-Uclaf Laboratory, Romainville, France) administered orally (300 mg daily for 1 month, then 150 mg daily). LHRH consisted of goseriline acetate (3.6 mg) or triptoreline (3.75 mg) administered monthly by subcutaneous injection. Treatment was given until death. Response was evaluated every 8 weeks according to World Health Organization (WHO) criteria. RESULTS Six patients were considered ineligible. One patient had a complete response (A+P arm) and three had a partial response (two in the LHRH+P arm and one in the A+LHRH arm). An overall log-rank test did not demonstrate any significant difference in survival among the four arms. Taking the factorial design into account, comparison of survival showed no significant difference between Anandron-containing regimens and others, or between LHRH-containing regimens and others. No serious side effects occurred for any regimen. CONCLUSION This controlled study shows clearly the lack of efficacy of androgen treatment in unresectable HCC.
APA, Harvard, Vancouver, ISO, and other styles
10

Celio, L., A. Martinetti, L. Ferrari, R. Buzzoni, E. Bombardieri, N. Zilembo, L. Maiorino, and E. Bajetta. "The LHRH analogue triptoreline (TAP) with or without the aromatase inhibitor formestane (4-OHA) in premenopausal advanced breast cancer: A study by the I.T.M.O. group." European Journal of Cancer 33 (September 1997): S155. http://dx.doi.org/10.1016/s0959-8049(97)85286-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Triptoreline"

1

Payafar, Alireza. "L'évaluation par l'I. R. M. Des fibromes utérins traités par la triptolérine." Montpellier 1, 1993. http://www.theses.fr/1993MON11144.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sinclair, Chelsea D. "The use of an intravaginal triptorelin gel to induce ovulation in the mare." Thesis, Kansas State University, 2016. http://hdl.handle.net/2097/32677.

Full text
Abstract:
Master of Science
Department of Animal Sciences and Industry
Joann M. Kouba
The objective of these studies was to investigate the efficacy of an intravaginal triptorelin acetate (TA) gel as an ovulation-inducing agent in mares. In Exp 1, 24 mares were stratified by parity and age and randomly assigned to 3 treatment groups receiving either: 5 mL TA gel (500 μg TA; TA5), 10 mL TA gel (1,000 μg TA; TA10), or 5 mL vehicle gel only (CON). Following the appearance of a follicle ≥ 25 mm, blood samples were obtained every 24 h until treatment administration for measurement of luteinizing hormone (LH) concentrations. Once a follicle ≥ 35 mm in diameter was detected, treatment was administered intravaginally. Following treatment, blood samples were collected and ovaries were scanned via transrectal ultrasonography every 12 h until 48 h post-ovulation. Both TA5 and TA10 tended (P = 0.08) to experience a brief surge in LH by 12 h post-treatment. Regarding LH concentrations, there was a significant (P < 0.005) treatment by time interaction. The interval from treatment to ovulation was not different (P > 0.05) between groups, nor was there a difference (P > 0.05) in the percentage of mares ovulating within 48 h of treatment administration. We hypothesized that LH was not staying elevated long enough for ovulation to occur in a greater percentage of mares. Furthermore, more frequent sampling and scanning was needed to get a more robust characterization of the effect of TA on LH and a more accurate timeframe for when ovulation was occurring. Experiment 2 involved the same CON and TA5 treatment groups; however, the TA10 treatment was split into two 5-mL doses of TA gel, administered 24 h apart (two 500-μg doses of TA; TA5x2). Blood collection and ultrasonography occurred every 12 h upon detection of a follicle ≥ 25 mm in diameter. Once a follicle ≥ 35 mm was detected, treatment was administered and ultrasonography and blood collection occurred every 6 h until 48 h post-ovulation. Both TA5 and TA5x2 had a significant increase (P < 0.05) in LH by 6 h post-treatment, which was declining by 12 h post-treatment. The second dose administered to TA5x2 failed to elicit an increase in LH (P > 0.05). Overall, the treatment by time interaction was significant (P < 0.005) in regard to LH and the interval from treatment to ovulation was shorter (P < 0.01) in TA5 and TA5x2 compared with CON. In conclusion, TA gel increased LH concentrations and hastened the interval from treatment to ovulation in mares in Exp. 2, but not Exp. 1, without an advantage in the timing of ovulation noted between the 5 or 10-mL doses, or administration of two 5-mL doses given 24 h apart. The results of these studies suggest that further testing is needed to effectively evaluate the efficacy of TA gel as an ovulation-inducing agent in mares.
APA, Harvard, Vancouver, ISO, and other styles
3

Meyer, Colette. "Characterisation of the direct antiproliferative effects of a gonadotrophin-releasing hormone analogue." Thesis, University of Edinburgh, 2012. http://hdl.handle.net/1842/6476.

Full text
Abstract:
Gonadotrophin-releasing hormone (GnRH) can inhibit proliferation of multiple reproductive tissue cancer cell lines through direct interaction with GnRH receptors (GnRHR) on tumour cells. GnRH analogues may therefore have a role in treating some cancers. The signalling pathways associated with these inhibitory effects are poorly defined, and characterising them may help to understand therapeutic sensitivity. To elucidate these pathways, transcriptomic and proteomic approaches were used to compare the effects of the GnRH agonist Triptorelin in responsive GnRHR-transfected HEK293 cells (SCL60) and unresponsive (HEK293) cells both in vitro for up to 24h and in vivo for up to 7 days. Gene expression profiling demonstrated that SCL60 gene expression was temporally regulated with Triptorelin treatment, with expression of some genes increased at one time point but decreased at another. Early and mid-phase gene expression changes comprised mainly transcription factors and late changes included the hormonal signalling component CGA. Pathway analysis implicated mitogen-activated protein kinase and cell cycle pathways, supporting the detection of G2/M arrest. Signalling effects within SCL60 xenografts, 4 and 7 days following Triptorelin treatment, were investigated using a phosphoproteomic antibody array. Changes included cell cycle and apoptosis regulators, as well as cell surface receptors and NFκB signalling pathway members. Reverse-phase protein arrays and western blotting also showed that pAkt was decreased and pNFκB-p65 was increased after Triptorelin treatment in vitro. An NFκB inhibitor enhanced the anti-proliferative effect of Triptorelin in SCL60 cells in vitro, suggesting that NFκB acts as a survival factor in the response to GnRHR stimulation. A range of GnRHR expression was observed in breast cancer tumours by immunohistochemistry, and on average GnRHR expression was significantly higher in the Triple Negative Phenotype (TNP) subgroup and in grade 3 tumours. A GnRHR-transfected breast cancer cell line, MCF7-h14, was developed. Despite this expressing a similar level of GnRHR to responsive SCL60 cells, MCF7-h14 cells were not inhibited by GnRHR activation, indicating that a high level of GnRHR is insufficient for the antiproliferative effects of Triptorelin.
APA, Harvard, Vancouver, ISO, and other styles
4

Heinze, Susanne. "Triptorelinazetat 2,1 mg versus Triptorelinazetat 4,12 mg zur ovariellen Suppression im Rahmen der In-vitro-Fertilisation." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2002. http://dx.doi.org/10.18452/14756.

Full text
Abstract:
Die GnRH-Agonisten-Applikation zur Downregulation vor IvF ist "gold standard", überwiegend im sogenannten langen Protokoll. Die Behandlung soll den vorzeitigen LH-Anstieg mit vorzeitiger Ovulation verhindern. Die unerwünschten Wirkungen sind dosisabhängig und rechtfertigen die Suche nach der optimal niedrigen Dosis des GnRH-Agonisten. Mit dieser Fragestellung wurde eine prospektive randomisierte Dosisfindungsstudie durchgeführt. 200 sterile Frauen zwischen 18 und 38 Jahren erhielten vor der IvF-Behandlung im langen Protokoll die Standarddosis von 4,12 mg Triptorelinazetat-Depot (1 Amp. i.m. = Gruppe B: n = 100) versus 2,1 mg Triptorelinazetat Depot (1/2 Amp. i.m = Gruppe A. n = 100) zur Downregulation. Folgende Parameter wurden bestimmt: E2, LH, Progesteron. Die Behandlungsergebnisse wurden korreliert mittels der Anzahl der gewonnenen Oocyten, der fertilisierten Oocyten, der transferierten Embryonen und der Schwangerschaftsraten pro Embryotransfer. Abgebrochene IvF-Zyklen wurden einzeln analysiert. Bezüglich der Hormonwerte waren beide Gruppen ohne signifikanten Unterschied. In der Gruppe der Patientinnen mit der halbierten Dosis (A) kam es nur in einem Fall zu einer vorzeitigen Luteinisierung, in der Standartdosisgruppe (B) in keinem Fall. Wegen low response wurde in Gruppe A in 5 Fällen die Therapie abgebrochen, versus 3 Fälle in Gruppe B (ns). Ebenfalls vergleichbar war das IvF-outcome, nur die ET-Rate pro begonnener Stimulation zeigte einen signifikanten Unterschied: 88 % (A) versus 96 % (B), p
The GnRH agonist application for the downregulation prior to IVF is 'gold standard', mainly in the so-called long protocol. This should avoid premature ovulations. The dose-dependent, undesired effects justify the search for the optimal low dose of the GnRH agonist. A prospective randomised dose-finding study was carried out in this respect. Among 200 sterile women (18 and 38 years) for the planned IVF and/or IVF / ICSI treatment in the long protocol, n = 100 in group A received 2.1 mg Triptorelinacetate depot (1/2 amp., i.m.) and n = 100 in group B the standard dose of 4.12 mg (1 amp., i.m.) for the downregulation. The hormone values E2, LH, progesterone were determined. The treatment results were compared by means of the number and quality of the oocoytes, the embryo transfers and the pregnancy rates. Cancelled IVF cycles were analysed. With respect to the hormone values, neither of the two groups showed significant differences. A premature luteinization occurred in group A (reduced dose) in only one case; in the standard dose of group B, none occurred. Due to the low response, the therapy was cancelled in 5 cases in group A, in comparison to 3 cases in group B (ns). The IVF outcome showed a comparable result. The only significant difference was the ET rate per started stimulation (p
APA, Harvard, Vancouver, ISO, and other styles
5

Fabi, Amanda Jean. "Use of Triptorelin Acetate for Inducing Ovulation and Facilitating Fixed Time Artificial Insemination of Sows Weaned on Small-Scale and Niche Market Pig Farms." Thesis, Virginia Tech, 2017. http://hdl.handle.net/10919/77395.

Full text
Abstract:
Developing a single fixed-time artificial insemination (FTAI) protocol would benefit small-scale and niche market pork producers by decreasing semen costs and labor associated with detection of estrus. The objective of this study was to test the efficacy of an artificial insemination (AI) breeding system using triptorelin acetate, a GnRH agonist (OvuGel®; JBS United Animal Health, LLC, Sheridan, IN) that induces ovulation. A total of 96 sows (parity, 3.5 ± 0.2; body condition score (BCS), 2.5 ± 0.07) were weaned (h 0) after a 24.8 ± 0.6 d lactation on five participating small swine farms and allocated to one of four treatment groups: 1) TRT1: (n = 24) OvuGel applied intravaginally at h 96 and AI at h 120; 2) TRT2: (n = 24) P.G. 600® (400 IU eCG and 200 IU hCG, Merck Animal Health, Inc., De Sota, KS) injected intramuscularly at weaning, OvuGel at h 96 and AI at h 120; 3) TRT3: (n = 24) P.G. 600 at weaning, and AI at 0 and 24 h after first detection of estrus; and 4) TRT4: (n = 24) AI at 0 and 24 h after first detection of estrus. Treatments 1 and 2 were FTAI protocols with sows being inseminated without regard to estrus onset. Treatments 3 and 4 were consistent with current industry AI practices. The proportion of females displaying estrus by d 7 post-weaning was greater (P < 0.05) for sows that received OvuGel (94.5 %) compared to sows that did not receive OvuGel (82.2 %). There were no effects (P > 0.05) of P.G. 600 or P.G. 600 x OvuGel on females displaying estrus by d 7 or d 10 post-weaning. Weaning to estrus interval was decreased (P < 0.05) for sows that received P.G. 600 (4.9 ± 0.4 d) compared to sows that did not receive P.G. 600 (5.4 ± 0.4 d). There were no effects (P > 0.05) of OvuGel or P.G. 600 x OvuGel on the weaning-to-estrus interval. There were no effects of P.G. 600, OvuGel or P.G. 600 x OvuGel (P > 0.1) on pregnancy rate (total sows pregnant/inseminated) (61.2 %), total litter size (11.3), number born dead (1.0) or number of mummies (0.2). There was an effect (P < 0.05) of P.G. 600 x OvuGel on total born live (10.2). Sows treated with OvuGel had a greater number of live piglets born per semen dose (5.4) compared to sows that did not receive OvuGel (3.2) (P < 0.05). These results suggest that FTAI protocols may be employed on small-scale pig farms without compromising reproductive performance.
Master of Science
APA, Harvard, Vancouver, ISO, and other styles
6

Klompen, Julia [Verfasser], and Carsten [Akademischer Betreuer] Gründker. "Expression des Gonadotropin-Releasing-Hormon (GnRH)-Rezeptors in primären humanen Osteoblasten und Effekte des GnRH-Agonisten Triptorelin auf die Expression osteoblastärer Gene / Julia Klompen. Betreuer: Carsten Gründker." Göttingen : Niedersächsische Staats- und Universitätsbibliothek Göttingen, 2010. http://d-nb.info/1042732337/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ribeiro, Ana Rita Salgado. "Development of Nanoparticle-in-Microparticle systems for oral delivery of triptorelin." Dissertação, 2018. https://hdl.handle.net/10216/111548.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ribeiro, Ana Rita Salgado. "Development of Nanoparticle-in-Microparticle systems for oral delivery of triptorelin." Master's thesis, 2018. https://hdl.handle.net/10216/111548.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Schmidt, Oswald [Verfasser]. "Effekte des LHRH-Agonisten Triptorelin auf die In-vitro-Proliferation verschiedener Ovarial- und Endometriumkarzinomzellinien / vorgelegt von Oswald Schmidt." 2005. http://d-nb.info/97790444X/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Klompen, Julia. "Expression des Gonadotropin-Releasing-Hormon (GnRH)-Rezeptors in primären humanen Osteoblasten und Effekte des GnRH-Agonisten Triptorelin auf die Expression osteoblastärer Gene." Doctoral thesis, 2010. http://hdl.handle.net/11858/00-1735-0000-0006-AF88-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Triptoreline"

1

Furman, Brian L. "Triptorelin." In xPharm: The Comprehensive Pharmacology Reference, 1–4. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.62810-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Furman, B. L. "Triptorelin☆." In Reference Module in Biomedical Sciences. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-801238-3.98037-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"TRIPTORELIN." In Litt's Drug Eruption Reference Manual Including Drug Interactions, 1568–73. CRC Press, 2004. http://dx.doi.org/10.3109/9780203492079-186.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Freire, Analia Veronica, Maria Eugenia Escobar, Mirta Gryngarten, Andrea Arcari, Maria Gabriela Ballerini, Marisol Morini, Ignacio Bergada, and Maria Gabriela Ropelato. "Novel GnRH Analog Test (Triptorelin)vs.Classical GnRH Test for the Early Diagnosis of Central Precocious Puberty (CPP) in Girls: Comparative Validation Study." In CLINICAL/TRANSLATIONAL - Pediatric Endocrinology: Puberty, P3–714—P3–714. The Endocrine Society, 2011. http://dx.doi.org/10.1210/endo-meetings.2011.part4.p13.p3-714.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Triptoreline"

1

Beni, Yousef, Samiyah Alhamed, Jawzah Alnakhli, Kaleh Karim, and William Boadi. "Abstract 2686: Polyphenolic triptorelin and leuprorelin derivatives as anticancer prodrugs." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2686.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Beni, Ryan, William Boadi, and Jawzah Alnakhli. "Abstract 4807: Triphenylmethanol conjugates of triptorelin as anti-cancer prodrugs." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4807.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bauerschmitz, G., JW Hellinger, G. Emons, and C. Gründker. "Reduzierte CTGF Expression in invasiven MDA-MB-231 Mammakarzinomzellen durch Behandlung mit GnRH Agonist Triptorelin." In 62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe – DGGG'18. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1670998.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hellinger, JW, G. Bauerschmitz, G. Emons, and C. Gründker. "Reduzierte RhoC Expression in mesenchymal transformierten Mammakarzinomzellen durch Behandlung mit GnRH Agonist Triptorelin beeinflusst Tumorinvasivität." In 62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe – DGGG'18. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1671038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zhang, X., V. Perrot, and H. Li. "EP1266 Assessment of effectiveness of post-operative triptorelin administration in alleviating gastrointestinal symptoms in patients with deep infiltrating endometriosis in a multicentre, non-interventional study." In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.1272.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mazza, M., A. Luini, P. Veronesi, M. Intra, V. Bagnardi, F. Sangalli, M. Iorfida, E. Munzone, and M. Colleoni. "Abstract P1-15-03: Preoperative endocrine treatment with letrozole ± triptorelin in patients with ER (estrogen receptor) and PgR (progesterone receptor) positive locally advanced breast cancer." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-p1-15-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zhang, X., V. Perrot, and H. Li. "EP1267 Assessment of efficacy of post-operative triptorelin in improving pain symptoms from deep infiltrating endometriosis: a 24-month multicentre, prospective, non-interventional study in highest pain intensity patient population." In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.1273.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Colleoni, M., K. Gray, E. Munzone, S. Dellapasqua, C. Zamagni, L. Gianni, H. Johansson, et al. "Abstract P1-10-06: A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for primary endocrine responsive breast cancer (TREND; IBCSG 41-13)." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p1-10-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Dellapasqua, S., M. Colleoni, and R. Maibach. "Abstract OT3-2-06: TREND: A randomized phase II clinical trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for locally advanced endocrine responsive breast cancer (IBCSG 41-13)." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-ot3-2-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bellet, M., K. Gray, P. Francis, I. Láng, E. Ciruelos, A. Lluch, M. Ángel Climent, et al. "Abstract P4-14-01: Estrogen levels in premenopausal patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p4-14-01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Triptoreline' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography